Optimal management of ADHD in older adults

Terje Torgersen1,2
Bjørn Gjervan3,5
Michael B Lensing6
Kirsten Rasmussen1,5

1Department of Østmarka, St Olav’s Hospital; 2Department of Neuroscience, Norwegian University of Science and Technology, Trondheim; 3Department of Psychiatry, Helse Nord-Trøndelag Hospital Trust, Kirkegata, Levanger, Norway; 4NevSom, Norwegian Center of Expertise for Neurodevelopmental Disorders and Hypersomnias, Women and Children’s Division, Oslo University Hospital, Oslo; 5St Olav’s Hospital, Broset Center for Research and Education in Forensic Psychiatry, Trondheim; 6Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway

Background: The manifestation of attention-deficit/hyperactivity disorder (ADHD) among older adults has become an interesting topic of interest due to an increasing number of adults aged 50 years and older (≥50 years) seeking assessment for ADHD. Unfortunately, there is a lack of research on ADHD in older adults, and until recently only a few case reports existed.

Method: A systematic search was conducted in the databases Medline/PubMed and PsycINFO in order to identify studies regarding ADHD in adults ≥50 years.

Results: ADHD persists into older ages in many patients, but the prevalence of patients fulfilling the criteria for the diagnosis at age ≥50 years is still unknown. It is reason to believe that the prevalence is falling gradually with age, and that the ADHD symptom level is significantly lower in the age group 70–80 years than the group 50–60 years. There is a lack of controlled studies of ADHD medication in adults ≥50 years, but this review suggests that many patients aged ≥50 years experience beneficial effects of pharmacological treatment. The problem with side effects and somatic complications may rise to a level that makes pharmacotherapy for ADHD difficult after the age of 65 years. Physical assessment prior to initiation of ADHD medication in adults ≥50 years should include a thorough clinical examination, and medication should be titrated with low doses initially and with a slow increase. In motivated patients, different psychological therapies alone or in addition to pharmacotherapy should be considered.

Conclusion: It is essential when treating older adult patients with ADHD to provide good support based on knowledge and understanding of how ADHD symptoms have affected health, quality of life, and function through the life span. Individualized therapy for each elderly patient should be recommended to balance risk–benefit ratio when pharmacotherapy is considered to be a possible treatment.

Keywords: ADHD, adults, older adults, pharmacotherapy, central stimulants

Introduction to ADHD in the older adult population (≥50 years)

Attention-deficit/hyperactivity disorder (ADHD) is a heterogeneous neurobiological disorder recognized today as a more dimensional rather than a categorical condition.1–3 The neurobiology of ADHD is underscored both by a high level of inheritance4,5 and numerous reports of structural and functional neuropathology.6–9

Studies show that the symptoms of ADHD persist into adulthood for at least two-third of the patients diagnosed with ADHD in childhood.10 The manifestation of ADHD among older adults has become an issue of growing interest due to an increasing number of adults aged 50 years and older (≥50 years) seeking assessment for ADHD for the first time. Unfortunately, there is a lack of research on ADHD in adults aged ≥50 years, and until recently only a few case reports existed.11–13

The prevalence of ADHD in adults aged ≥50 years is a question yet to be answered. In a large, epidemiological study by Kessler et al,14 the prevalence of ADHD in adults...
was estimated to be 4.4%. This important study did not include patients older than 44 years old. In contrast to this, in a European population-based study, 50% of the study sample was older than 45 years (range: 18–75 years), and the prevalence of ADHD in this sample was 1.0%–2.5%.\(^15\)

Some recent studies have investigated the prevalence of ADHD in adults aged ≥50 years and found prevalence rates below the previous estimates for adult ADHD\(^{16–18}\) (Table 1). In a Dutch epidemiological study, 1,419 adult participants aged 55–85 years were studied. The prevalence of symptomatic ADHD was 2.8% and symptomatic ADHD was 4.2%.\(^{16}\) The results also showed that younger elderly adults (60–70 years) reported more ADHD symptoms than the older group (71–94 years). The Australian PATH Through Life Project also found that older-age adults (68–74 years) reported significantly lower levels of ADHD symptoms as measured by ASRS screener\(^{16}\) than middle-aged adults (48–52 years). Approximately 2.2% of the older-age adults met the suggested cut-off for the Adult ADHD Self-Report Scale (ASRS)-screener score that has been linked to a clinical diagnosis of ADHD, versus 6.2% in the middle-aged group.\(^{18}\)

In a Swedish population-based study of 2,500 persons aged 65–80 years, the authors found the prevalence of self-rated childhood ADHD to be 3.3%.\(^{17}\) A methodological problem in this study is the dependence on retrospectively experienced childhood symptoms recalled 50–70 years later. The risk for recall bias, and both under- and overestimation of symptoms, is probably high.\(^{20}\)

These three epidemiological studies indicate that the prevalence of ADHD symptoms appears to decline to 1.0%–2.8% in the oldest ages.\(^{16–18}\) Some authors discuss the impact of lower life length expectancy in patients with ADHD,\(^{21}\) due to greater rates of accidents, substance abuse, mood disorders, and other health issues, resulting in a relative decline of people with ADHD by age. The lack of age-appropriate diagnostic criteria for adult ADHD may also explain some of the apparent decline in ADHD prevalence in older adults, as discussed by several authors.\(^{16–18}\) Simon et al discuss in their meta-analysis the problem with validity of DSM criteria for diagnosing adult ADHD and assume that a strict use of the criteria may lead to an underestimation of the prevalence of ADHD in adults.\(^{22}\) Another factor is the occurrence of health-related issues in adults aged ≥50 years, making the differential diagnostic assessment related to an ADHD diagnosis difficult. Examples of such issues are mild cognitive impairment (MCI),\(^{23}\) dementia, and other neurodegenerative disorders, increasing polypharmacy, sleep disturbances, chronic pain and other physical conditions, and impaired vision and hearing. Despite the lack of research on ADHD in adults aged ≥50 years, and many unanswered questions about prevalence and persistence of ADHD throughout the life span, there is reason to believe that ADHD or residual ADHD persists into middle age and late adulthood in a large number of patients. A number of recent studies from different countries using national registers and prescription databases have shown that a growing number of patients aged ≥50 years are assessed and treated for ADHD worldwide.\(^{24–27}\)

**Procedure**

A systematic search was conducted in the databases Medline/PubMed and PsycINFO to identify studies regarding ADHD in adults aged ≥50 years. Search terms were “ADHD AND older adults” published up to date. The resulting list of papers was screened to find papers for this review, and the reference lists in the relevant papers were further screened to find other papers of relevance.

**How does ADHD affect the older adult patient?**

**ADHD symptoms across the life span**

The core symptoms of ADHD are persisting inattentiveness, impulsivity, and hyperactivity. Despite the persistence of symptoms, the presentation of symptoms will often change over the course of development. The overt signs

---

**Table 1** Studies regarding the prevalence of ADHD in adults ≥50 years

<table>
<thead>
<tr>
<th>N</th>
<th>Age; range (years)</th>
<th>Age; mean (years)</th>
<th>Procedure</th>
<th>Measures</th>
<th>Prevalence of ADHD (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kooij et al(^{15})</td>
<td>1,813</td>
<td>18–75</td>
<td>–</td>
<td>Interview</td>
<td>1.0–2.5</td>
</tr>
<tr>
<td>Michielsen et al(^{16})</td>
<td>231</td>
<td>60–70</td>
<td>71</td>
<td>Interview</td>
<td>4.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>71–94</td>
<td>DIVA 2.0(^{17})</td>
<td>1.1</td>
</tr>
<tr>
<td>Das et al(^{18})</td>
<td>1,907</td>
<td>48–52</td>
<td>50.7</td>
<td>Interview</td>
<td>6.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1,536</td>
<td>ASRS screener(^{19})</td>
<td>2.2</td>
</tr>
<tr>
<td>Guldberg-Kjar and Johansson(^{17})</td>
<td>1,599</td>
<td>65–80</td>
<td>72.0</td>
<td>Questionnaire</td>
<td>3.3</td>
</tr>
</tbody>
</table>

**Abbreviations:** ASRS, Adult ADHD Self-Report Scale; ADHD, attention-deficit/hyperactivity disorder; DIVA, Diagnostic Interview ADHD in adults. Second Edition; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; WURS, Wender Utah Rating Scale.
of hyperactivity and impulsivity in children with ADHD will often decline with increasing age, while symptoms of inattentiveness often will continue unchanged. The motor hyperactivity in children with ADHD is in adults often replaced by an “inner” hyperactivity in the form of restlessness, excessive fidgeting and talking, inability to relax, and difficulty to sit quietly for long periods. Impulsivity in adulthood may appear as outbursts of anger, impatience, careless driving, and making decisions without thinking. Inattention will manifest as disorganization, forgetfulness, poor performance in planning and completion of tasks, task shifting, and time management. Because of this developmental change in symptom expression, many adults will not fully exhibit the criteria for the diagnosis, while still remaining significantly impaired.

In addition to the core symptoms, ADHD in adults is strongly associated with emotional dysregulation (ED). The concept of ED includes symptoms such as increased irritability, low tolerance for frustration and stress, and emotional lability. Recent research indicates, however, that ED is not as specific for ADHD as previously assumed.

### Comorbidity

ADHD in all ages is associated with the presence of psychiatric comorbidity. Studies have shown that comorbidity can have a negative impact on treatment outcome in ADHD across the life span. Recent studies indicate that psychiatric comorbidity mostly occurs during childhood and adolescence, and more seldom have onset after the age of 20 years. A recent study by Rasmussen et al suggests that living longer without receiving central stimulant (CS) treatment may lead to an increase in comorbid psychiatric problems. The comorbid disorders most strongly associated with adult ADHD are anxiety disorders, mood disorders, antisocial personality disorder, and substance use disorders.

Most studies of comorbidity in adult ADHD are done in samples of young adults up to 40 years. The developmental alteration of comorbid disorders into middle-aged and older samples is poorly understood. We have identified only a few studies presenting data on comorbidity in samples of adults aged ≥50 years. A Dutch study, with average sample age 71 years (range: 60–94 years), found that participants with ADHD had more depressive and anxiety symptoms than participants without ADHD. In another paper presenting data from the same study, the authors found that older adults with ADHD had significantly lower self-esteem and sense of mastery, and higher levels of neuroticism and social inadequacy, than older adults without ADHD. Self-esteem and sense of mastery partly explained the association between ADHD and depressive symptoms. Semeijn et al found that the risk of depression in older adults with ADHD was partly explained by serious conflicts and adverse life events. In this study, lower cognitive functioning was also explained by depressive symptoms.

In a sample of adults aged ≥50 years with ADHD from Norway (mean age: 55.7 years), 46.7% of the participants reported psychiatric comorbidity, depression 36.7%, anxiety 26.5%, and bipolar disorder 24.5%. The sample was recruited from the national ADHD organization, and not necessarily representative for adults aged ≥50 years with ADHD. In a small study of 27 patients from the US, recruited from psychiatrists in private practice, 63% of the participants reported having other mental health conditions, depression 54%, anxiety 42%, and bipolar disorder 8%.

In the older population, the prevalence of dementia increases steadily with advancing age. MCI is a diagnosis designed as a predictor of prodromal degenerative dementia, and its prevalence in the geriatric population is estimated to 16%. MCI includes cognitive problems in older ages that do not meet the criteria for dementia, and results in no or minimal functional impairment. In a review by Ivanchak et al, the authors discuss the role of ADHD as a predisposing factor for MCI and more manifest degenerative disease in late life, but conclude that such an association is less than convincing. On the contrary, a clinical study from Argentina found an association between childhood ADHD and dementia with Lewy bodies, but not with Alzheimer’s disease. The authors have no explanation for this association between ADHD and dementia with Lewy bodies, but discuss the role of dopaminergic dysfunction in both diseases.

There has been a growing interest in somatic comorbidity in ADHD. A number of somatic diseases have been found to have an association to ADHD in children, adolescence, and young adults, such as obesity, musculoskeletal pain, asthma, and allergy. The association between somatic diseases and ADHD in older adults is largely unknown. In Lensing et al’s study of 149 adults aged ≥50 years with ADHD, 46.6% reported co-occurring somatic disorders. Hypothyroidism 20.6%, hypertension 19.1%, fibromyalgia 16.2%, and arthritis 16.2% were the most common disorders. Another finding from the same sample showed that 73.7% of the patients reported moderate-to-severe pain/discomfort on EuroQoL, in comparison to 43.8% in the age- and sex-matched population norm. In a small sample of eleven clinically recruited patients with mean age 61.6 years, 55% had somatic disorders like hypertension, type 2 diabetes, and ischemic heart disease.
a study comparing 23 older adults with 208 controls without ADHD, the authors could not find significant differences in a number of somatic diseases, like chronic lung disease, cardiovascular disease, diabetes, arthritis, and cancer. In an adjusted regression analysis, they found, however, that the number of ADHD symptoms was associated with the presence of chronic lung disease, cardiovascular disease, and number of somatic diseases. Interestingly, the authors found no association between ADHD and an unhealthy lifestyle.

Impairment
A number of controlled follow-up studies have shown that ADHD in young adults is associated with impairment in several life domains, such as academic, occupational, and social functioning. In a study of 148 adults aged ≥50 years with ADHD (mean age 55.7 years), compared to an age group-matched reference sample, the ADHD patients were significantly more often single (41.5% versus 25.2%) and less frequently employed (48.8% versus 69.2%). Surprisingly, in this study the level of education was not different between groups. The study showed that adults aged ≥50 years with ADHD reported significantly reduced quality of life compared to population norms. A Dutch study that recruited patients with a mean age 68 years also found a significantly higher level of divorced/never married in the ADHD group compared to the non-ADHD group (26.1% versus 10.1%). They also found that ADHD was associated with having fewer family members in their network and experiencing emotional loneliness. Because of the presence of only a few studies, relatively small samples, and different age groups, it is not possible to draw definitive conclusions about impairment in adults aged ≥50 years with ADHD. However, the results indicate that the negative impact of ADHD seems to persist into late adulthood. In a paper based on a study of 24 clinically referred older adults with ADHD, Brod et al found that the quality of life suffers from the accumulated negative impact of ADHD symptoms and impairments on their professional, economic, social, and emotional well-being. At the same time, none of the patients in this study indicated worsening of ADHD symptoms with aging, and some stated that living with ADHD got easier with age. Similar findings are also described by the patients in the paper by Henry and Jones.

Pharmacological treatment of ADHD in older adults
Older adults are underrepresented in pharmacokinetic and pharmacodynamic studies, leading to a lack of knowledge and understanding of pharmacologic treatment in this age group. Very few studies regarding pharmacotherapy of ADHD in older adults are published. We know, however, that the problem with polypharmacy and drug–drug interactions is growing in older adults. With aging, a series of changes occur that modify the pharmacokinetics and pharmacodynamics of psychotropic medication. This may influence the efficacy, tolerability, and safety of any psychopharmacologic treatment. Pharmacological treatment in older adults should generally follow similar guidelines as with younger patients except that drug dosing and speed of titration should be slower and start lower. Side effect profile is a greater consideration than with younger patients. In a paper by Sajatovic, the author listed some key clinical issues among older adults prescribed psychotropic medication; they generally have a reduced capacity to metabolize drugs, and are relatively sensitive to medication-associated side effects.

Pharmacological treatment has been the cornerstone in management of ADHD for decades, and numerous studies have proven its efficacy in reducing ADHD symptoms in all age groups. CS are recommended as first-line treatment, and have a well-documented short-term effect on symptoms. Little is known about effects on long-term outcomes like mortality, symptom level, impairment, and quality of life. A few open and naturalistic studies indicate a long-term beneficial effect from CS therapy in adults, but there is a lack of controlled studies lasting more than a few weeks.

In our search we could not find controlled studies of pharmacologic treatment of ADHD in the age group ≥50 years, but a few naturalistic studies have been published (Table 2). In 2011, Manor et al described eleven adults aged 55+ diagnosed with ADHD for the first time. Mean age was 62 years, and male–female ratio 9:2. All patients were treated with methylphenidate (MPH) and followed for at least 2 months with moderate doses (eight patients tried MPH immediate release in daily doses between 20 and 35 mg, two patients MPH long acting agents 60–80 mg, and one patient tried osmotic-release oral system MPH 72–108 mg). At follow-up, only two patients had stopped using the medication, and eight patients showed significant improvement on the test of variables of attention. No adverse events were reported. The authors concluded that this group of middle-aged and older ADHD patients had a similar response to MPH as younger adults.

Brod et al explored the burden of illness and impact of ADHD on quality of life in 24 patients with mean age 66 years. Information was collected by telephone interviews. All patients had been taking ADHD medication at some point after being diagnosed. Most patients reported a beneficial effect of medication, and found themselves being able to be more organized, understand written text better, and be more focused. Some patients reported medication side effects, such
All patients had been taking ADHD medication at some time, and currently 64% used some type of ADHD medication at some time following diagnosis, and 88% of the participants had been treated with ADHD medication at some time, and most patients reported a beneficial effect of medication and reported significantly lower levels of ADHD symptoms as measured by ASRS screener than middle-aged adults (48–52 years). This decline in ADHD symptoms may lead to a diminishing efficacy of medication in older ages. Another finding substantiating a reduced efficacy with age is a study by Volkow et al, showing an age-related decline in dopamine transporter capacity. The atomoxetine study by Durell et al showing lower effect sizes in the middle-aged group (mean age 43.4 years) than in the younger adults may point in the same direction, suggesting that age may be a predictor of reduced efficacy of pharmacological treatment in adult ADHD. Further research is needed in this field.

In addition to the issue of efficacy of ADHD medication in adults aged ≥50 years, there is a concern about side effects. The most common side effects of CS are reduced appetite, nausea, dry mouth, insomnia, anxiety, and headache. The geriatric population (age >65 years) may, due to a changing physiology, be predisposed to adverse events, and relatively harmless side effects may impact the individual more negatively than in younger adults. Weight loss because of reduced appetite is probably more harmful for the health in an elderly person, and insomnia as a side effect may add to the higher prevalence of sleep problems we find in the geriatric population. In one study of treatment with MPH for apathy in Alzheimer’s disease, two patients experienced serious adverse events consisting of delusions, agitation, anger, irritability, and insomnia. Another safety concern when treating older persons with CS is the risk to exacerbate an attack of glaucoma.

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; MPH IM, methylphenidate immediate release; MPH LA, methylphenidate long acting; MPH, methylphenidate; OROS, osmotic-release oral system.

Table 2 
Naturalistic studies of pharmacological treatment of ADHD in adults ≥50 years

<table>
<thead>
<tr>
<th>Author</th>
<th>N</th>
<th>Mean age (years)</th>
<th>Pharmacologic treatment</th>
<th>Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manor et al&lt;sup&gt;50&lt;/sup&gt;</td>
<td>11</td>
<td>62</td>
<td>All patients treated with MPH and at least 2 months, eight showed improvement</td>
<td>MPH IM 20–35 mg (N=8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MPH LA 60–80 mg (N=2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OROS MPH 72–108 mg (N=1)</td>
</tr>
<tr>
<td>Brod et al&lt;sup&gt;51&lt;/sup&gt;</td>
<td>24</td>
<td>66</td>
<td>All patients had been taking ADHD medication at some time, and most patients reported a beneficial effect of medication</td>
<td>Self-reported mean daily dose: MPH 54.1 mg (range: 8–135 mg) Amphetamine 29.5 mg (range: 4–50 mg)</td>
</tr>
<tr>
<td>Lensing et al&lt;sup&gt;52&lt;/sup&gt;</td>
<td>149</td>
<td>56</td>
<td>88% of the participants had been treated with ADHD medication at some time following diagnosis, and 64% used some type of ADHD medication 5 years after diagnosis</td>
<td></td>
</tr>
</tbody>
</table>

As nausea, sleepiness, insomnia, overexcitement, headache, and anxiety.

Recently, Lensing et al<sup>53</sup> presented the results from a study of 149 members of a national ADHD patient organization aged ≥50 years. Mean age was 55.8 years, and mean age diagnosed with ADHD was 50.3 years. Approximately 88% of the participants had been treated with ADHD medication at some time following diagnosis, and currently 64% used some type of ADHD medication. The self-reported mean daily dose for MPH was 54.1 mg (range: 8–135 mg) and for amphetamine was 29.5 mg (range: 4–50 mg). The currently medicated group was compared with a group that had stopped medication and a medication-naive group. The only significant difference between groups was that the group currently on medication reported better attention when compared to 10 years ago than the nonmedicated groups. The mean score on the ASRS screener was not significantly different between the groups in this study. The most important finding is probably that a majority of the participants received ADHD medication for longer periods and in doses comparable to the doses given to younger adults.

We were unable to identify any studies addressing treatment with atomoxetine for ADHD in adults aged ≥50 years, but one relevant paper presented data from a post hoc analysis using data from two double-blind, placebo-controlled clinical trials of atomoxetine in adult ADHD. Data from young adults (mean age 21.7 years) were compared with data from older adults (mean age 43.4 years) and larger effect sizes for the younger group than the older group was found, as measured by the Conner’s Adult ADHD Rating Scale<sup>78</sup> (0.797 versus 0.326). The authors argue that this difference is primarily due to greater variability of response in older patients. When looking at side effects, the only significant difference between groups was more sexual side effects in the older group.

The papers described in this review show that CS treatment is used in adults aged ≥50 years in different countries like US, Israel, and Norway in doses comparable to doses used in younger adults. In these naturalistic studies, the patients report beneficial effects of medication, but we do not know the effect sizes due to the lack of controlled study design. There is, however, some data indicating a reduction of the effect of CS in older ages. Several studies have shown that higher level of ADHD symptoms at baseline predict better efficacy of CS treatment in adult ADHD. At the same time, the results from the Australian PATH Through Life Project<sup>18</sup> showed that older-age adults (68–74 years) reported significantly lower levels of ADHD symptoms as measured by ASRS screener than middle-aged adults (48–52 years). This decline in ADHD symptoms may lead to a diminishing efficacy of medication in older ages.
There is a concern that CS treatment in ADHD may be associated with adverse cardiovascular events, but the findings are mixed.\textsuperscript{83} Westover and Halm,\textsuperscript{83} in their review, state that studies of adults show an increased risk for transient ischemic attacks and sudden death, but interpretation is limited mostly due to methodological problems. Recently a large, Danish nationwide cohort study found that the use of CS increased the risk for cardiovascular adverse events in children and adolescents. Cardiovascular adverse events were rare, but twice as likely in CS users compared to nonusers.\textsuperscript{86} Despite a low risk in most patients, the clinicians must take precautions when it comes to middle-aged and older adults, because of the general increased risk of cardiovascular disease in this population. Older patients may also be more vulnerable to the increased blood pressure and the increased heart rate often experienced by patients using CS. Physical assessment prior to initiation of ADHD medication in adults aged $\geq$ 50 years should include a thorough clinical examination, medical history, and electrocardiogram. Heart rate, blood pressure, and weight should be taken before and during treatment.

**Psychological treatment and support**

Although pharmacological treatment is generally considered the first choice of treatment in adults with ADHD, it is rarely sufficient. In addition to the limiting factors discussed above, there are more general factors which may reduce the effect of drug therapy, like poor compliance to medication and lack of continuity of medication.\textsuperscript{87} In addition, the high prevalence of comorbid psychiatric disorders, inefficient compensatory strategies, and maladaptive thoughts may reduce the potential for drug efficacy in adult ADHD.

Throughout the last 10–15 years, several studies reporting effects of psychological treatment on adult ADHD have been published. We identified several controlled studies of psychotherapy for adult ADHD in our search, but none of the identified studies were specifically investigating psychological treatment in adults aged $\geq$ 50 years. However, Solanto et al\textsuperscript{88} investigated the efficacy of meta-cognitive therapy (MCT) in a group format for adults with a diagnosis of ADHD aged between 18 and 65 years, comparing MCT with supportive therapy. The participants (N=88) were stratified by ADHD medication and randomized to either MCT or supportive therapy. MCT is described as an intervention where cognitive behavioral principles are employed to provide contingent self-reward, skills in dismantling complex tasks into manageable units, and sustaining motivation. Participants were assigned to either MCT (n=45) or supportive therapy (n=43) in a group format during a 12-week treatment or supportive intervention. Participants in the MCT condition achieved significant greater improvement in attention and memory scores on Conner’s Adult ADHD Rating Scales subscale\textsuperscript{79} compared to the supportive treatment group.

In a blinded randomized, placebo-controlled, parallel-group study, Weiss et al\textsuperscript{89} compared individual cognitive behavioral therapy (CBT) and Dexedrine (CBT/DEX) with CBT and placebo (CBT/PLB) in a sample with age ranging between 18 and 66 years. The therapy was administered individually for nine sessions. ADHD symptoms were measured by the investigator administered ADHD-Rating Scale-Investigator.$^{78}$ There were no statistical differences between CBT/DEX and CBT/PLB at baseline or in follow-up, and both groups showed robust improvement over time. Results for the Sheehan Disability Scale\textsuperscript{80} showed that the CBT/DEX group improved in functioning by week 15 and that this improvement sustained at week 20. The CBT/PLB group also showed improvement in functioning at week 15, but this improvement attenuated slightly at week 20.

In addition to these two studies including adults aged $\geq$ 50 years, several studies are published showing efficacy of different forms of psychotherapy in younger adults with ADHD.\textsuperscript{91–93} We assume that these therapies will be useful also in adults $\geq$ 50 years, as long as they have normal cognitive function, sufficiently remaining senses, and of course, are motivated. Despite the fact that none of the studies had a particular focus on adults aged $\geq$ 50 years, several studies have shown that older adults are treated with psychological therapies in different countries.\textsuperscript{53,88} In psychological therapy with adults aged $\geq$ 50 years, common life-stage issues should be included in therapy if relevant, such as physical illness, retirement and job loss, loss of societal and financial status, and changes in interpersonal relationships due to illness or death.

**Conclusion**

The papers included in this review indicate that ADHD persists into older age in many patients, but the prevalence of patients fulfilling the criteria for the diagnosis at ages $\geq$ 50 years is still unknown. It is reason to believe that the prevalence is falling gradually with age and that the ADHD symptom level is significantly lower in the age group 70–80 years than the group 50–60 years. Both the diagnostic assessment and treatment of ADHD may be more difficult for the clinician in older patients, as the clinical picture gets more complicated when age-related health issues appear in middle-aged and older adults with ADHD. There is a lack of controlled studies of ADHD medication in adults aged $\geq$ 50 years, but this review suggests that many patients aged $\geq$ 50 years experience beneficial effects of pharmacological treatment with minimal side effects. It is,
however, reason to believe that the chance of getting a satisfactory effect is lower after reaching geriatric age (65 years and older) for most patients. The problem with side effects and somatic complications may also rise to a level that makes pharmacotherapy for ADHD difficult after the age of 65 years. Given these aspects, individualized therapy for each elderly patient should be recommended to balance risk–benefit ratio when pharmacotherapy is considered to be a possible treatment. Physical assessment prior to initiation of ADHD medication in adults aged ≥50 years should include a thorough clinical examination, and medication should be titrated with low doses initially and a slow increase. In motivated patients, different psychological therapies alone or in addition to pharmacotherapy should be considered. It is essential when treating older adult ADHD patients to provide good support based on knowledge and understanding of how ADHD symptoms have affected health, quality of life, and function through the life span.

Disclosure

The authors report no conflicts of interest in this work.

References


